NCT02482272View on ClinicalTrials.gov

Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

PHASE4UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

May 31, 2017

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Lamivudine

Lamivudine 100mg/day orally

DRUG

Adefovir

Adefovir 10mg/day orally

DRUG

Entecavir

Entecavir 1mg/day orally

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER